Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of May 20, 2026, VRTX trades at $432.75 with a market cap of $110.81B and a P/E ratio of 25.21. VRTX moved -0.91% today. Year to date, VRTX is -3.94%; over the trailing twelve months it is -1.44%. Its 52-week range spans $362.50 to $519.88. Analyst consensus is strong buy with an average price target of $565.30. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vertex Pharmaceuticals Q1 EPS Hits $4.47 Despite $2.99B Revenue Miss, Barclays Sees 45% Upside: Barclays upped its price target for Vertex Pharmaceuticals to $615 from $607, implying a 44.92% upside. In Q1, Vertex posted $2.99 billion in revenue, just below projections, while delivering adjusted earnings of $4.47 per share and seeing new products contribute over 25% of growth.
| Metric | Value |
|---|---|
| Price | $432.75 |
| Market Cap | $110.81B |
| P/E Ratio | 25.21 |
| EPS | $17.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $519.88 |
| 52-Week Low | $362.50 |
| Volume | 1.43M |
| Avg Volume | 0 |
| Revenue (TTM) | $12.22B |
| Net Income | $4.34B |
| Gross Margin | 86.24% |
23 analysts cover VRTX: 0 strong buy, 19 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $565.30.